Oregon Oncology COVID 19

Viewing Page 1 of 1 | Showing Results 1 - 4 of 4

A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19

The primary objectives are:Phase 1• To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo• To evaluate the virologic...

Jason Wells, M.D.
  • Providence Portland Medical Center
  • Providence St. Vincent Medical Center

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study.

This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test...

Gary Goodman, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

Plasma Adsorption in Patients With Confirmed COVID-19

To characterize the ability of the D2000 Cartridge in combination with the Optia SPD Protocol to reduce the morbidity and mortality associated with...

Jason Wells, M.D.
  • Providence Portland Medical Center

A phase I rapid access trial of 2019-nCoV spike (S) protein plasmid DNA vaccine in combination with IL-12p70 plasmid (CORVax-12) in healthy volunteers, with immunodynamic monitoring of coordinated cellular/humoral response

This is a Phase 1, open-label study to evaluate the safety profile of CORVax +/- pIL-12, (electroporated SARS-CoV-2 spike (S) protein plasmid DNA...

Rom Leidner, M.D.
  • Providence Portland Medical Center
Viewing Page 1 of 1 | Showing Results 1 - 4 of 4